Popular Trials
Immunosuppressant
Sirolimus +1 More for Aplastic Anemia
Recruiting3 awardsPhase 1 & 2
Los Angeles, California
Aplastic anemia is a rare autoimmune disorder in which the bone marrow production of blood cells is greatly decreased or absent. Symptoms include fatigue, weakness, tiny reddish-purple marks on the skin, abnormal bruising, and bleeding from the gums, nose, or intestine. While some cases of aplastic anemia are caused by medications, toxic exposures, or inherited genes, most often the cause remains unknown. The purpose of this study is to determine the safety and efficacy of combining two drugs, sirolimus and cyclosporine, for treating individuals with aplastic anemia that has not responded to other treatments.
Alkylating agents
Combination Chemotherapy + Cyclosporine and Focal Therapy for Retinoblastoma
Recruiting1 awardPhase 2
Vancouver, British Columbia
This trial is studying a combination of chemotherapy drugs with or without cyclosporine followed by cryotherapy (freezing) and/or laser therapy in treating patients with newly diagnosed retinoblastoma in both eyes.
Alkylating agents
GVHD Prophylaxis Regimens for Blood Cancer Stem Cell Transplant
Recruiting1 awardPhase 2
Seattle, Washington
This trial is studying two different drug combinations to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following a blood stem cell transplant from an unrelated donor to treat blood cancer.
MEK Inhibitor
Selumetinib + Cyclosporine for Colorectal Cancer
Recruiting1 awardPhase 1
Sacramento, California
This trial studies the combination of Selumetinib and Cyclosporine in patients with advanced cancers that do not respond to standard treatments. Selumetinib blocks growth signals in cancer cells, while Cyclosporine helps by modifying the immune system. Cyclosporine is an immunosuppressive drug that has been used in human transplants and autoimmune diseases, and it has been approved for use in dermatology for many years.
Popular Filters
Phase 3 Trials
Virus Therapy
Alipogene Tiparvovec (AMT-011) for Lipoprotein Lipase Deficiency
Recruiting3 awardsPhase 2 & 3
Chicoutimi, Quebec
LPLD is a rare autosomal recessive disorder, characterized by the presence of marked chylomicronemia and hence hypertriglyceridemia. Clinically the most severe manifestation of chylomicronemia, is acute pancreatitis, which can be lethal. There is no effective therapy available to modulate the course of the illness and prevent complications for these patients. The current clinical management consists of severe reduction of dietary fat that is hard if not almost impossible to comply with. LPLD subjects continue to experience pancreatitis attacks, and are admitted to intensive care units on several occasions. Alipogene tiparvovec corrects or restores lipoprotein lipase (LPL) function long term, and hence reverses some symptoms, halts the disease progression and prevents further complications. Alipogene tiparvovec gene therapy ensures that a catabolically beneficial variant of the human LPL gene, LPL\[S447X\] is expressed and active in the relevant tissues in humans. Delivery of the gene is realized via intramuscular injection of an adeno-associated viral vector, pseudotyped with AAV1 capsids.
Immunomodulator
Etanercept vs Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
Recruiting1 awardPhase 3
Nashville, Tennessee
This trial is testing whether two therapeutic interventions (etanercept vs cyclosporine) are better than supportive care alone for treating Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Immunosuppressant
L-CsA + Standard of Care for Bronchiolitis Obliterans Syndrome
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing how safe and effective L-CsA plus Standard of Care is in treating Breathing Obstruction Syndrome in people who have had either a single or double lung transplant.
Trials With No Placebo
Virus Therapy
Alipogene Tiparvovec (AMT-011) for Lipoprotein Lipase Deficiency
Recruiting3 awardsPhase 2 & 3
Chicoutimi, Quebec
LPLD is a rare autosomal recessive disorder, characterized by the presence of marked chylomicronemia and hence hypertriglyceridemia. Clinically the most severe manifestation of chylomicronemia, is acute pancreatitis, which can be lethal. There is no effective therapy available to modulate the course of the illness and prevent complications for these patients. The current clinical management consists of severe reduction of dietary fat that is hard if not almost impossible to comply with. LPLD subjects continue to experience pancreatitis attacks, and are admitted to intensive care units on several occasions. Alipogene tiparvovec corrects or restores lipoprotein lipase (LPL) function long term, and hence reverses some symptoms, halts the disease progression and prevents further complications. Alipogene tiparvovec gene therapy ensures that a catabolically beneficial variant of the human LPL gene, LPL\[S447X\] is expressed and active in the relevant tissues in humans. Delivery of the gene is realized via intramuscular injection of an adeno-associated viral vector, pseudotyped with AAV1 capsids.
Monoclonal Antibodies
Rituximab + Cyclosporine for Glomerulonephritis
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing the safety and effectiveness of combining two drugs to treat membranous nephropathy, a kidney disease associated with damage to the walls of the glomeruli. The first drug, rituximab, is an immunosuppressant that attempts to reduce the activity of the immune system. The second drug, cyclosporine, is a blood pressure lowering medication. The trial will last up to 2 years, and participants will have frequent blood and urine tests.
Alkylating agents
Cord Blood Transplant + Chemo/Radiation for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Aurora, Colorado
This trial is testing whether giving an umbilical cord blood transplant together with chemotherapy and radiation therapy works better than just giving an umbilical cord blood transplant for treating patients with hematologic disease.
Immunosuppressant
Thymoglobulin for Transplant Rejection
Recruiting5 awardsPhase 4
Vancouver, British Columbia
This study has been designed to test whether using Thymoglobulin with low dose Cyclosporine and early steroid dosage reduction will minimize both kidney rejection and the development of new onset diabetes mellitus after renal transplant.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.